Skip to main content
Clinical Trials/NL-OMON37216
NL-OMON37216
Not yet recruiting
Phase 3

Autologous bone marrow-derived mononuclear cells for therapeutic arteriogenesis in patients with limb ischemia A double blind placebo controlled study in diabetic and non-diabetic patients - Autologous bone marrow for peripheral artery disease.

eids Universitair Medisch Centrum0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
claudication
Sponsor
eids Universitair Medisch Centrum
Enrollment
100
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with persistent (\>3 months, despite optimal treatment) disabling claudication or with critical leg ischemia (Fontaine's stages IIb\-IV or Rutherford's categories 3\-6\) without adequate options for improvements by PTA or reconstructive surgery will be included in the study.

Exclusion Criteria

  • candidates for angioplasty or bypass procedures
  • \-inability to undergo bone marrow harvesting
  • \-any condition in the affected limb that is anticipated to require surgical intervention in the first weeks after BM\-MNC treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials